Precipio (PRPO) Planet MicroCap Las Vegas 2026 summary

Key milestones and financial outlook

• Achieved profitability as of Q3 2025, following a previous capital raise and a commitment to financial independence.

• Ended 2025 with a $25 million run rate, with 90% from legacy lab services and 10% from products; aiming for a 60/40 split in 3–5 years.

• Projected 30% revenue growth and 275% share price increase by Q3 2025.

• Expansion into cancer genetics and molecular diagnostics markets is expected to increase total addressable market from $0.5B to $43B over five years.

• Recurring revenue growth and a shift toward high-margin products are anticipated to drive gross margins above 50% in the long term.

Product innovation and clinical impact

• Developed a four-hour HemeScreen Rapid AML panel and a rapid 4-hour CAML test for Acute Myeloid Leukemia, enabling same-day actionable results and immediate, targeted treatment.

• Platform addresses misdiagnosis and diagnostic delays, with 25-40% of blood cancer diagnoses historically incorrect and typical molecular testing turnaround times exceeding 10 days.

• Products offer simplified workflows, lower labor skill requirements, reduced capital equipment costs, and faster results compared to competitors.

• R&D is highly capital-efficient due to integration with the clinical lab, providing free access to equipment, staff, and patient samples.

• Assays are updated regularly to reflect advances in science and clinical needs.

Market strategy and customer relationships

• Distribution partnerships with major players like Thermo Fisher, McKesson, and other national healthcare channel partners provide access to established lab customers and broad market reach.

• Sales team expanded sixfold in 2025 to drive growth, with a new Chief Commercial Officer leading efforts.

• Maintains direct relationships with customers post-introduction, ensuring deep engagement and predictable demand.

• Currently serves 15 customers, with hundreds of potential targets; customer retention is 100% to date.

• Customers include hospital labs, reference labs, and physician office labs, purchasing both directly and via distributors.